EirGenix Inc. (TPE:6589)
49.10
+0.30 (0.61%)
Oct 20, 2026, 1:30 PM CST
EirGenix Revenue
EirGenix had revenue of 312.31M TWD in the quarter ending June 30, 2026, with 35.43% growth. This brings the company's total for the last twelve months to 1.21B, up 27.00% year-over-year. In the year 2025, EirGenix had annual revenue of 1.01B, down -0.38%. That makes EirGenix the 29,936th largest company in the world by revenue and 1,465th in Taiwan.
Revenue (ttm)
1.21B
Revenue Growth
+27.00%
P/S Ratio
12.09
Revenue / Employee
1.21M
Employees
1,000
Market Cap
14.66B
Revenue by Geography
- Japan 504.14M 50.2%
- Taiwan 349.88M 34.8%
- Europe 131.27M 13.1%
- America and Canada 12.78M 1.3%
- Other 6.64M 0.7%
- Hong Kong and Macau, China 442.00K 0.0%
Fiscal year ended Dec 31, 2025 See the full EirGenix breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.01B | -3.80M | -0.38% |
| Dec 31, 2024 | 1.01B | -13.69M | -1.34% |
| Dec 31, 2023 | 1.02B | -458.36M | -30.95% |
| Dec 31, 2022 | 1.48B | -216.34M | -12.75% |
| Dec 31, 2021 | 1.70B | 625.52M | 58.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.19B |
| Ever Supreme Bio Technology | 1.08B |
| TCM Biotech International | 701.63M |
| TaiMed Biologics | 619.49M |
| Medigen Vaccine Biologics | 573.85M |
| Oneness Biotech | 153.78M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 42.22M |